Alergia a la vacuna Pfizer-BioNTech® demostrada mediante pruebas cutáneas

• Published in: Revista alergia Mexico (Tecamachalco, Pueblo, Mexico : 1993) Vol. 69; no. 2; pp. 89 - 92
• Main Authors: Estrada García, Carlos David, Macías Robles, Ana Paola, Cortés Grimaldo, Rosa María, Carvajal Alonso, Hilda Lilian, Barreto Alcalá, Marlen, Ramírez Nepomuceno, Adriana, Esparza Amaya, David, Coronado Hernández, Kareli Guadalupe, Barrios Díaz, Britza, Campos Téllez, Héctor Hugo
• Format: Journal Article
• Language: Spanish
• Published: Colegio Mexicano de Inmunología Clínica y Alergia, A.C 31.05.2023
• Subjects: Alergia; Anafilaxia; Pfizer-BioNTech; Polietilenglicol; Pruebas cutáneas

Background: The Pfizer-BioNTech BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered. Case presentation: 30-year-old female, health professional, history of allergic rhinitis, asthma,...